Japan fully approves first biosimilar G-CSF but price process means launch delay
This article was originally published in Scrip
Executive Summary
Japan has wasted no time issuing a formal approval for its first biosimilar version of the recombinant granulocyte colony-stimulating factor (G-CSF) filgrastim, granting full regulatory clearance to a product co-developed by Mochida and Fuji Pharma.